Telix Pharmaceuticals Ltd

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutic and diagnostic radiopharmaceuticals, a specialized class of drugs that combine radioactive elements with antibodies or small molecules to target cancer cells. The company operates three business segments: Precision Medicine, which encompasses diagnostic imaging agents; Therapeutics, focused on treatment candidates; and Manufacturing Solutions for radiopharmaceutical production. Its most advanced program, TLX591, is a lutetium-labeled radio antibody-drug conjugate in Phase 3 trials for advanced prostate cancer. The company also markets Illuccix and Gozellix, approved diagnostic agents for prostate cancer imaging, representing its primary commercialized revenue stream.

The pipeline includes multiple therapeutic candidates across oncology indications. TLX250 targets metastatic kidney cancer, while TLX101 addresses glioblastoma. Earlier-stage programs include TLX592 and TLX102 utilizing proprietary targeted alpha therapy technology, and TLX66 for hematopoietic stem cell transplant conditioning. Diagnostic development includes BiPASS, a Phase 3 prostate cancer diagnostic tool, alongside radiochemistry platforms like AlFluor and associated PET imaging agents.

Based in North Melbourne, Australia, and incorporated in Australia, Telix operates across six regions including the United States, United Kingdom, Belgium, and Canada. The company employs approximately 1,120 full-time staff and maintains a collaboration with University Hospital Essen for developing artificial intelligence-based diagnostic models in prostate cancer. Founded in 2015, the company is listed on Nasdaq.